WT1 126-134 (HLA-A*02:01) peptide

WT1 126-134 (HLA-A*02:01) peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

H-RMFPNAPYL-OH

H-Arg-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu-OH

9

95.71%

C₅₂H₇₇N₁₃O₁₂S

1108.31

Synthetic

Powder

RMFPNAPYL is a linear peptidic epitope (epitope ID54882) studied as part of Wilms tumor protein from Homo sapiens (human). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays WT-1 126-134 peptide RMFPNAPYL (HLA-A*02:01) for stimulation of T cells. Single peptide (RMFPNAPYL) for stimulation of human WT 1-specific CD8+ T cells.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual:Handling and Storage of Synthetic Peptides

• Augsberger C, Hänel G, Xu W, Pulko V, Hanisch LJ, Augustin A, Challier J, Hunt K, Vick B, Rovatti PE, Krupka C, Rothe M, Schönle A, Sam J, Lezan E, Ducret A, Ortiz-Franyuti D, Walz AC, Benz J, Bujotzek A, Lichtenegger FS, Gassner C, Carpy A, Lyamichev V, Patel J, Konstandin N, Tunger A, Schmitz M, von Bergwelt-Baildon M, Spiekermann K, Vago L, Jeremias I, Marrer-Berger E, Umaña P, Klein C, Subklewe M. Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody. Blood. 2021 Dec 23;138(25):2655-2669. doi: 10.1182/blood.2020010477. Erratum in: Blood. 2022 Mar 31;139(13):2086-2087. PMID: 34280257; PMCID: PMC9037755.

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.